前沿生物跌1.9% 2020上市见顶两募资共20.44亿

Core Viewpoint - Frontline Bio (688221.SH) is currently trading at 19.63 yuan, reflecting a decline of 1.90% and is in a state of post-IPO price drop [1] Group 1: IPO Details - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total share capital post-issuance, at a price of 20.50 yuan per share [1] - The total funds raised from the IPO amounted to 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [2] - The company planned to use the raised funds for various projects, including the development of an HIV fusion inhibitor, clinical research for a combined therapy, and marketing network construction [2] Group 2: Financials and Shareholder Information - The actual controller of Frontline Bio is Dong Xie, who holds U.S. nationality and has permanent residency in China [3] - In a subsequent issuance on September 22, 2022, Frontline Bio issued 14.818 million shares at a price of 13.51 yuan per share, raising a total of approximately 200.2 million yuan, with a net amount of about 195.67 million yuan after deducting issuance costs [3] - The total amount raised from both fundraising rounds is approximately 2.044 billion yuan [4]